Wilbanks Smith & Thomas Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4,767	Closed	-$348K	–	539
2023 Q3	$348K	Buy	+4,767	New	+$381K	0.01%	374
2023 Q2	–	Sell	-2,887	Closed	-$220K	–	534
2023 Q1	$220K	Hold	2,887	–	–	0.01%	471
2022 Q4	$240K	Sell	2,887 -319	-10%	-$25.8K	0.01%	431
2022 Q3	$254K	Sell	3,206 -76	-2%	-$6.41K	0.01%	396
2022 Q2	$244K	Buy	+3,282	New	+$246K	0.01%	416
2018 Q4	–	Sell	-50	Closed	-$5K	–	1319
2018 Q3	$5K	Buy	+50	New	+$4.85K	﹤0.01%	1241

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

CHP

Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.4% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's XBI Position: Q4 2023 in Review

Wilbanks Smith & Thomas Asset Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2023, closing a stake of 4,767 shares — an estimated $348K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in XBI in Q3 2018 and held it in 6 quarters. The position peaked at $348K in Q3 2023. 746 funds tracked by Wall St. Rank hold XBI as of Q4 2023.

Wilbanks Smith & Thomas Asset Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2023 after selling out during the quarter.
Wilbanks Smith & Thomas Asset Management sold 4,767 State Street SPDR S&P Biotech ETF shares in Q4 2023, an estimated $348K.
Wilbanks Smith & Thomas Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2018 and held it in 6 quarters.
Wilbanks Smith & Thomas Asset Management's State Street SPDR S&P Biotech ETF position peaked at $348K in Q3 2023.
746 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2023.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2023, filed 6 Feb 2024.